Toll Free: 1-888-928-9744

Grass Pollen Allergy - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Grass Pollen Allergy - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Grass Pollen Allergy - Pipeline Review, H1 2015', provides an overview of the Grass Pollen Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Grass Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Grass Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Grass Pollen Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Grass Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Grass Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Grass Pollen Allergy Overview 7
Therapeutics Development 8
Pipeline Products for Grass Pollen Allergy - Overview 8
Pipeline Products for Grass Pollen Allergy - Comparative Analysis 9
Grass Pollen Allergy - Therapeutics under Development by Companies 10
Grass Pollen Allergy - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Grass Pollen Allergy - Products under Development by Companies 14
Grass Pollen Allergy - Companies Involved in Therapeutics Development 15
ALK-Abello A/S 15
Allergy Therapeutics plc 16
Anergis SA 17
Biomay AG 18
BioTech Tools s.a. 19
Circassia Pharmaceuticals plc 20
HAL Allergy BV 21
Laboratorios LETI S.L. 22
Roxall Medizin GmbH 23
Grass Pollen Allergy - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
AllerG - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Allergen Extract Of Phleum Pratense - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Avanz Phleum Pratense - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BM-32 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
clustoid wiesenlieschgras - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
gpASIT + TM - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
grass allergy vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Grass-SPIRE - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Pollinex Quattro Grass - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
timothy grass pollen allergen extract - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Grass Pollen Allergy - Recent Pipeline Updates 46
Grass Pollen Allergy - Dormant Projects 50
Grass Pollen Allergy - Product Development Milestones 51
Featured News & Press Releases 51
Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 51
Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 51
Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 52
Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 53
Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 53
Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 54
Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 54
Dec 06, 2013: Ethical committee of the University of Leuven approves a follow-up of the Phase IIa clinical study BTT006 to confirm a 2 years lasting immunological impact of 5 injections of gp-ASIT+TM 55
Nov 18, 2013: Update on Biotech Tools Phase IIa clinical study in the grass pollen allergy therapy 55
Nov 09, 2013: Merck's Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59
List of Tables
Number of Products under Development for Grass Pollen Allergy, H1 2015 8
Number of Products under Development for Grass Pollen Allergy - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2015 15
Grass Pollen Allergy - Pipeline by Allergy Therapeutics plc, H1 2015 16
Grass Pollen Allergy - Pipeline by Anergis SA, H1 2015 17
Grass Pollen Allergy - Pipeline by Biomay AG, H1 2015 18
Grass Pollen Allergy - Pipeline by BioTech Tools s.a., H1 2015 19
Grass Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015 20
Grass Pollen Allergy - Pipeline by HAL Allergy BV, H1 2015 21
Grass Pollen Allergy - Pipeline by Laboratorios LETI S.L., H1 2015 22
Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Assessment by Combination Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Grass Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2015 46
Grass Pollen Allergy - Dormant Projects, H1 2015 50 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify